ezetimibe has been researched along with Atheroma in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (75.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busk, M; Bøtker, HE; Dey, D; Fonte, T; Grove, EL; Hosbond, S; Iraqi, N; Jensen, JM; Leipsic, J; Mathiassen, ON; Mortensen, MB; Narula, J; Nørgaard, BL; Sand, NP; Updegrove, A | 1 |
| Li, C; Li, Z; Liang, D; Tu, Y; Zhang, M | 1 |
| Akiyama, Y; Eshima, K; Higo, T; Hironaga, K; Ichi, I; Inoue, S; Kadokami, T; Katsuki, S; Kishimoto, J; Matoba, T; Miyata, K; Mukai, Y; Nagata, T; Nakano, Y; Nakashiro, S; Oi, K; Sadamatsu, K; Suematsu, N; Takase, S; Takemoto, M; Todaka, K; Tsutsui, H; Usui, M; Yamamoto, M | 1 |
| Genkel, VV; Shaposhnik, II | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Lu, WQ; Meng, PN; Wu, XQ; Wu, ZM; Xu, T; Ye, F; Yin, DL; You, W | 1 |
| Angeli, V; Azhar, SH; Balachander, A; Chew, HS; Koh, XH; Lim, HY; Lim, SY; Ng, LG; Phua, ML; See, WQ; Tan, C; Tan, Y; Tang, Y; Thiam, CH; Yeo, KP; Zhao, MH | 1 |
| Ha, K; Han, SH; Jang, AY; Kang, WC; Kim, M; Lee, K; Moon, J; Oh, PC; Suh, SY | 1 |
| Fujisue, K; Tsujita, K | 1 |
| De Simone, B; Di Taranto, MD; Fortunato, G; Gentile, M; Giacobbe, C; Iannuzzi, A; Iannuzzo, G; Jossa, F; Marotta, G; Rubba, P; Sodano, M | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 1 |
| Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Antoku, Y; Egashira, K; Honda, K; Ichi, I; Koga, JI; Matoba, T; Nakano, K; Tsutsui, H | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamashita, T | 1 |
| Bajnok, L | 1 |
| Fazio, S; Weitz, JI | 1 |
| Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Maehara, A; Mintz, GS; Thayssen, P | 1 |
| Asakura, Y; Habara, M; Ito, T; Kimura, M; Kinoshita, Y; Ko, E; Kurita, T; Matsubara, T; Nasu, K; Suzuki, T; Teramoto, T; Terashima, M; Tsuchikane, E; Yokota, D | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Ono, T; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 3 |
| Jiang, Y; Li, L; Wang, X; Yao, H; Zhang, J; Zhao, X | 1 |
| Chen, Z; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Lopez, JJ; Skalicka, H; Sonka, M; Wahle, A; Zhang, L | 1 |
| Anderson, JD; Berr, SS; Chew, JD; Christopher, JM; DiMaria, JM; Epstein, FH; Hagspiel, KD; Harthun, NL; Hunter, JR; Kramer, CM; Meyer, CH; Wang, H; West, AM; Winberry, GB | 1 |
| Boyden, T; Khanderia, U; Regal, RE; Rubenfire, M | 1 |
| Abela, GS; Abela, OG; Aziz, K; Berger, K; Janoudi, A; Patel, R; Rubinstein, J; Tamhane, U; Vedre, A | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Kawaguchi, R | 1 |
| Bogiatzi, C; Spence, JD | 1 |
| Egashira, K; Katsuki, S; Matoba, T; Nakano, K; Osada, K; Sato, K; Sawamura, T; Sunagawa, K | 1 |
3 review(s) available for ezetimibe and Atheroma
| Article | Year |
|---|---|
Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Plaque, Atherosclerotic; Proprotein Convertase 9; Subtilisins; Triglycerides; Ultrasonography, Interventional | 2022 |
Current status of lipid management in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; PCSK9 Inhibitors; Plaque, Atherosclerotic | 2017 |
The ezetimibe controversy: implications for clinical practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Plaque, Atherosclerotic | 2011 |
19 trial(s) available for ezetimibe and Atheroma
| Article | Year |
|---|---|
Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study.
Topics: Angina, Stable; Atorvastatin; Ezetimibe; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Tomography, X-Ray Computed | 2022 |
Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxysterols; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome | 2023 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Spectroscopy, Near-Infrared; Ultrasonography, Interventional | 2021 |
Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Color; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Prospective Studies; Renal Insufficiency, Chronic | 2018 |
Influence of Ezetimibe on Plaque Morphology in Patients with ST Elevation Myocardial Infarction Assessed by Optical Coherence Tomography: An OCTIVUS Sub-Study.
Topics: Coronary Artery Disease; Coronary Vessels; Ezetimibe; Humans; Plaque, Atherosclerotic; ST Elevation Myocardial Infarction; Tomography, Optical Coherence | 2020 |
Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Tomography, Optical Coherence | 2014 |
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Ultrasonography, Interventional | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease.
Topics: Aged; C-Reactive Protein; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Interleukin-6; Male; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Ultrasonography, Interventional | 2016 |
Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Prospective Studies; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Time Factors; Ultrasonography, Interventional; User-Computer Interface | 2017 |
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Peripheral Arterial Disease; Plaque, Atherosclerotic; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden.
Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Triglycerides | 2012 |
10 other study(ies) available for ezetimibe and Atheroma
| Article | Year |
|---|---|
[Pleiotropic effects of ezetimibe].
Topics: Anticholesteremic Agents; Ezetimibe; Humans; Inflammation; Plaque, Atherosclerotic | 2019 |
Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Rosuvastatin Calcium; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Efficient aortic lymphatic drainage is necessary for atherosclerosis regression induced by ezetimibe.
Topics: Animals; Aorta; Atherosclerosis; Ezetimibe; Lymphangiogenesis; Mice; Plaque, Atherosclerotic | 2020 |
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Topics: Age of Onset; Anticholesteremic Agents; Apolipoprotein B-100; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; DNA Mutational Analysis; Ezetimibe; Genetic Association Studies; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Italy; Mutation; Mutation Rate; Phenotype; Plaque, Atherosclerotic; Prevalence; Proprotein Convertase 9; Receptors, LDL; Retrospective Studies; Risk Factors; Treatment Outcome | 2017 |
Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Arterial Occlusive Diseases; Atherosclerosis; Biomarkers; Cells, Cultured; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxysterols; Plaque, Atherosclerotic; Rabbits; Rats; Rosuvastatin Calcium; Signal Transduction; Thrombosis; Vascular System Injuries | 2018 |
[Newer evidences and recommendations in lipidology].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Plaque, Atherosclerotic | 2018 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Plaque, Atherosclerotic; Rivaroxaban; Thrombosis | 2019 |
Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography.
Topics: Animals; Anticholesteremic Agents; Aorta; Azetidines; C-Reactive Protein; Cholesterol; Crystallization; Ezetimibe; Fluorodeoxyglucose F18; Male; Plaque, Atherosclerotic; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Thrombosis | 2011 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Brachiocephalic Trunk; Chemokine CCL2; Cholesterol, Dietary; Ezetimibe; Flow Cytometry; Gas Chromatography-Mass Spectrometry; Immunohistochemistry; Liver; Lymphocyte Activation; Male; Mice; Mice, Knockout; Monocytes; Oxidation-Reduction; Oxidative Stress; Plaque, Atherosclerotic; Receptors, CCR2; Sterols | 2012 |